{"id":"W3028527898","doi":"10.1016/j.annonc.2020.03.245","title":"144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Servier; Eisai; Daiichi-Sankyo; Daiichi Sankyo Europe; Université de Liège; Curtin University of Technology; Incyte; Gilead Sciences; FibroGen; Merck KGaA; Genomic Health; Ariad Pharmaceuticals; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; PharmaMar; Celgene; BC Cancer Agency; Centro de Investigación Biomédica en Red de Cáncer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Progression-free survival; Fulvestrant; Placebo; Breast cancer; Oncology; Cancer; Urology; Gastroenterology; Overall survival; Estrogen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001771643,0.0004535285,0.001426151,0.0002386011,0.00004699414,0.000007727705,0.0001463361,0.0002387102,0.0004728593],"category_scores_gemma":[0.00008570559,0.0003482666,0.0001112824,0.0006476474,0.0003384279,0.0002477912,0.00005368159,0.0004630585,0.000004030203],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001341995,"about_ca_system_score_gemma":0.000430024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001099571,"about_ca_topic_score_gemma":0.003864475,"domain_scores_codex":[0.9972773,0.0001044344,0.000996328,0.0007033699,0.0003227384,0.0005958432],"domain_scores_gemma":[0.9982556,0.0002087662,0.0005447475,0.0003424924,0.0003460907,0.0003022937],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02567098,0.001333023,0.627448,0.000185295,0.0005771003,0.00106059,0.002774967,0.0009827901,0.01056464,0.00003707748,0.00005541773,0.3293101],"study_design_scores_gemma":[0.03021056,0.01470746,0.9196525,0.0004198879,0.0000852758,0.0005438704,0.000853077,0.0002531497,0.01711579,0.0003913011,0.01519524,0.0005718771],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9635848,0.003182079,0.00001735646,0.03152166,0.00006234762,0.001112205,0.0001710285,0.00007122815,0.0002772305],"genre_scores_gemma":[0.9884799,0.002826257,0.0004384653,0.007682928,0.00007193816,0.0002377462,0.0000603802,0.00007047127,0.0001319517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3287382,"threshold_uncertainty_score":0.9998969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05540093340937784,"score_gpt":0.357927209976405,"score_spread":0.3025262765670271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}